Bruckner H W, Lokich J J, Stablein D M
Cancer Treat Rep. 1982 Sep;66(9):1713-7.
In this multi-institutional study of advanced gastric cancer, 73 patients were evaluable for response or survival. Patients were treated with either triazinate (Baker's antifol), standard-dose methotrexate, or ICRF-159 (razoxane). Objective responses were seen in four patients receiving Baker's antifol, in three receiving methotrexate, and in none receiving razoxane. Baker's antifol produced a median survival of 18 weeks and methotrexate and razoxane produced a median survival of 8 and 9 weeks, respectively. Seventy of the 73 patients entered in this study had been previously treated, most frequently with combination chemotherapy regimens containing 5-FU or doxorubicin. This study appears to demonstrate that Baker's antifol is an active drug for patients with advanced gastric cancer, according to both response and survival criteria. Examination of the pretreatment prognostic characteristics of the patients further suggests that a possible survival advantage is due to treatment with Baker's antifol rather than the prognostic characteristics of the patients.
在这项针对晚期胃癌的多机构研究中，73例患者可评估疗效或生存期。患者接受三嗪酸盐（贝克抗叶酸剂）、标准剂量甲氨蝶呤或ICRF - 159（丙亚胺）治疗。接受贝克抗叶酸剂治疗的4例患者、接受甲氨蝶呤治疗的3例患者出现了客观缓解，而接受丙亚胺治疗的患者无一出现缓解。贝克抗叶酸剂的中位生存期为18周，甲氨蝶呤和丙亚胺的中位生存期分别为8周和9周。参与本研究的73例患者中有70例曾接受过治疗，最常见的是接受含5 - 氟尿嘧啶或阿霉素的联合化疗方案。根据缓解和生存标准，本研究似乎表明贝克抗叶酸剂对晚期胃癌患者是一种有效的药物。对患者治疗前预后特征的检查进一步表明，可能的生存优势归因于贝克抗叶酸剂治疗而非患者的预后特征。
